Pharmaron Beijing Co., Ltd. Class H (HK:3759)
:3759
Top Page
Pharmaron Beijing Co., Ltd. Class H
(3759)
Select Model
Select Model
Rating:63Neutral
Price Target:
HK$22.50
▼(-6.79% Downside)
Action:ReiteratedDate:04/05/26
The score is driven primarily by solid overall financial stability and a strengthening balance sheet, offset by slowing growth, margin compression, and inconsistent free cash flow. Technicals and valuation add caution: the trend is mixed with only modest near-term strength, and the P/E is relatively high with a low dividend yield.
Positive Factors
Integrated R&D-to-manufacturing model
Pharmaron's end-to-end service platform (discovery, preclinical/clinical development, CDMO) creates durable client stickiness and cross-sell opportunities. Long-term contracts and multi-stage engagements raise lifetime value, diversify revenue sources and reduce single-project cyclicality.
Negative Factors
Slowing revenue growth
A marked deceleration in top-line growth reduces operating leverage and future earnings upside. If the trend persists it may signal increased competition or weaker demand for services, constraining long-term margin expansion and the firm's ability to scale higher-margin offerings.
Read all positive and negative factors
Positive Factors
Negative Factors
Integrated R&D-to-manufacturing model
Pharmaron's end-to-end service platform (discovery, preclinical/clinical development, CDMO) creates durable client stickiness and cross-sell opportunities. Long-term contracts and multi-stage engagements raise lifetime value, diversify revenue sources and reduce single-project cyclicality.
Read all positive factors
Pharmaron Beijing Co., Ltd. Class H (3759) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$57.11B
Dividend Yield1.04%
Average Volume (3M)3.76M
Price to Earnings (P/E)18.6
Beta (1Y)1.98
Revenue Growth14.50%
EPS Growth-19.24%
CountryHK
Employees21,370
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.34
Shares Outstanding359,977,870
10 Day Avg. Volume3,469,725
30 Day Avg. Volume3,761,430
Financial Highlights & Ratios
PEG Ratio-2.69
Price to Book (P/B)2.06
Price to Sales (P/S)2.20
P/FCF Ratio56.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$29.93Price Target Upside24.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)1.3
Revenue Forecast (FY)HK$18.45B
Pharmaron Beijing Co., Ltd. Class H Business Overview & Revenue Model
Company Description
Pharmaron Beijing Co., Ltd. Class H (3759) is a leading contract research organization (CRO) offering a comprehensive range of R&D and manufacturing services to the pharmaceutical and biotechnology sectors. Founded in Beijing, China, Pharmaron pro...
How the Company Makes Money
Pharmaron makes money primarily by providing fee-for-service, contract-based R&D and manufacturing services to pharmaceutical and biotechnology clients. Key revenue streams typically include: (1) Laboratory research and discovery services (e.g., c...
Pharmaron Beijing Co., Ltd. Class H Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
78
Positive
Cash Flow
56
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 14.10B | 12.28B | 11.54B | 10.27B | 7.44B |
| Gross Profit | 4.91B | 4.20B | 4.12B | 3.77B | 2.68B |
| EBITDA | 3.29B | 3.38B | 2.95B | 2.53B | 2.49B |
| Net Income | 1.66B | 1.79B | 1.60B | 1.37B | 1.66B |
Balance Sheet | |||||
| Total Assets | 27.09B | 23.93B | 26.48B | 20.49B | 18.39B |
| Cash, Cash Equivalents and Short-Term Investments | 1.73B | 2.81B | 6.72B | 2.24B | 5.10B |
| Total Debt | 3.42B | 5.54B | 9.36B | 6.12B | 5.29B |
| Total Liabilities | 11.36B | 9.70B | 13.24B | 9.65B | 8.09B |
| Stockholders Equity | 15.06B | 13.62B | 12.56B | 10.55B | 10.13B |
Cash Flow | |||||
| Free Cash Flow | 551.97M | 536.02M | -111.78M | -807.04M | -34.78M |
| Operating Cash Flow | 3.22B | 2.58B | 2.75B | 2.14B | 2.06B |
| Investing Cash Flow | -4.37B | -2.02B | -2.25B | -2.21B | -5.26B |
| Financing Cash Flow | 377.00M | -4.80B | 3.92B | -1.42B | 3.66B |
Pharmaron Beijing Co., Ltd. Class H Technical Analysis
Positive
24.14
Price Trends
19.92
Positive
20.99
Negative
21.56
Negative
Market Momentum
-0.06
Negative
60.58
Neutral
84.94
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:3759, the sentiment is Positive. The current price of 24.14 is above the 20-day moving average (MA) of 19.04, above the 50-day MA of 19.92, and above the 200-day MA of 21.56, indicating a neutral trend. The MACD of -0.06 indicates Negative momentum. The RSI at 60.58 is Neutral, neither overbought nor oversold. The STOCH value of 84.94 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:3759.
Pharmaron Beijing Co., Ltd. Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | HK$48.87B | 20.04 | 6.54% | 1.57% | 12.35% | 34.32% | |
63 Neutral | HK$57.11B | 18.63 | 11.48% | 1.04% | 14.50% | -19.24% | |
56 Neutral | HK$26.89B | -6.48 | -12.75% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | HK$40.58B | -22.62 | -14.53% | ― | 38.56% | 48.26% | |
45 Neutral | HK$17.86B | -10.93 | -22.81% | ― | 23.87% | 30.08% |
* Healthcare Sector Average
HK:3759
Pharmaron Beijing Co., Ltd. Class H
20.98
9.36
80.47%
HK:1548
Genscript Biotech
12.36
2.56
26.12%
HK:9688
Zai Lab Ltd
15.78
-5.82
-26.94%
HK:1877
Shanghai Junshi Biosciences Co., Ltd. Class H
26.38
13.70
108.04%
HK:2096
Simcere Pharmaceutical Group Limited
13.62
6.44
89.69%
HK:6821
Asymchem Laboratories (Tianjin) Co., Ltd. Class H
102.50
60.54
144.28%
Pharmaron Beijing Co., Ltd. Class H Corporate Events
Pharmaron Lifts Revenue and Cash Flow in 2025 Despite Profit Dip
Mar 30, 2026
Pharmaron Beijing Co., Ltd. reported 2025 revenue of RMB14.10 billion, up 14.8% year on year, driven by continued expansion of its contract research and manufacturing services for global pharmaceutical clients. Despite higher administrative and RD...
Pharmaron Beijing Plans 2025 Final Cash Dividend Payout
Mar 30, 2026
Pharmaron Beijing Co., Ltd. has proposed a final ordinary cash dividend of RMB 2 per 10 shares for the financial year ended 31 December 2025, with the Hong Kong dollar equivalent, key dates, and applicable withholding tax details to be announced. ...
Pharmaron Beijing Revamps Governance Roles and Formalizes Registered Capital Increase
Mar 30, 2026
Pharmaron Beijing announced a management reshuffle, with company secretary and authorised representative Mr. Yim Lok Kwan resigning effective March 30, 2026, and experienced governance professional Ms. Mak Po Man Cherie stepping in as company secr...
Pharmaron Schedules Board Meeting to Review 2025 Results and Potential Dividend
Mar 16, 2026
Pharmaron Beijing Co., Ltd. has scheduled a board meeting for March 30, 2026 to review and approve the annual results for the financial year ended December 31, 2025. The board will also consider whether to recommend a final dividend, a decision th...
Pharmaron Says New Manufacturing Deal Is Within Ordinary Course of Business
Mar 12, 2026
Pharmaron Beijing Co., Ltd. has confirmed that its recently reported manufacturing collaboration with the Chinese subsidiary of a leading global pharmaceutical company is a normal commercial arrangement conducted in the ordinary and usual course o...
Pharmaron Raises HK$1.32 Billion via H-Share Placement to Fund Capacity Expansion
Jan 22, 2026
Pharmaron Beijing Co., Ltd. has completed a placing of 58,440,762 new H shares under its general issuance mandate, raising net proceeds of approximately HK$1.32 billion through placements to at least six independent investors at HK$22.82 per share...
Pharmaron Beijing to Raise Capital via HK$22.82-per-Share H-Share Placement
Jan 14, 2026
Pharmaron Beijing Co., Ltd. has entered into a placing agreement with Goldman Sachs (Asia) L.L.C. and The Hongkong and Shanghai Banking Corporation Limited to issue 58,440,762 new H shares at HK$22.82 per share under its existing general issuance ...
Pharmaron Forecasts Strong 2025 Revenue and Core Profit Growth Despite Drop in Headline Net Profit
Jan 13, 2026
Pharmaron Beijing Co., Ltd. has issued an estimate for its 2025 annual results, projecting revenue between RMB 13.87 billion and RMB 14.24 billion, representing a year-on-year increase of 13% to 16%. Despite this top-line growth and an expected 36...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.